News Conference News TCT 2015 PFO Closure Still Attracts Controversy Yael L. Maxwell October 14, 2015
News Conference News TCT 2015 MISTRAL-C: Cerebral Protection in TAVR May Reduce New Lesions October 14, 2015
News Conference News EuroPCR 2015 DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device Yael L. Maxwell May 20, 2015
News Conference News ACC 2015 DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume Yael L. Maxwell March 16, 2015
News Conference News ACC 2015 Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR Yael L. Maxwell March 15, 2015
News Conference News TCT 2014 Capture Devices Hold Promise for Decreasing TAVR-Related Stroke September 15, 2014
News Conference News ESC 2014 SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year Todd Neale September 01, 2014
News Conference News ACC 2014 Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure Yael L. Maxwell March 29, 2014
News Conference News TCT 2013 Clamping Intolerance Predicted by Low Clamping Pressure in Carotid Stenting November 07, 2013
News Conference News ESC 2013 ASSURE: RVX-208 Fails to Stall or Reverse CAD Progression vs. Placebo September 02, 2013
News Conference News EuroPCR 2013 EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges Caitlin E. Cox May 29, 2013
News Conference News EuroPCR 2013 Deflection Device Reduces Volume, Not Number, of Cerebral Lesions During TAVR Jason Kahn May 24, 2013
News Conference News TCT 2012 Successful Device Innovation Focuses on Clinical Needs, Multidisciplinary Approach October 23, 2012
News Conference News TCT 2012 Review of TAVR Use Offers Significant Advances, Positive Outcomes October 22, 2012
News Conference News TCT 2012 Israeli Innovations Include ‘Cath Lab of the Future,’ Stent and Digital Developments October 22, 2012
News Conference News ACC 2012 CORONARY Bypass Shows Similar Results Whether On-Pump or Off Jason Kahn March 26, 2012
News Conference News Complications After TAVR: Manageable, But Important to Consider November 09, 2011